Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Sponsor: Lexeo Therapeutics
Summary
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
Official title: A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2026-06-25
Completion Date
2032-06
Last Updated
2026-07-22
Healthy Volunteers
No
Interventions
LX2006
Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Usual Care
Cohort 1: Participants ≥16 years of age with FA-CM Participants will receive usual care for 26 weeks before receiving treatment with LX2006 (single crossover).
Locations (1)
University of South Florida
Tampa, Florida, United States